A DC‐based vaccine, in which DCs are pulsed with tumor membrane vesicles (TMVs) and incorporated with glycolipid‐anchored immunostimulatory molecules (GPI‐ISMs) were tested in HER2‐positive and triple negative breast cancer murine models. Here, ERBB2 is linked to neoplasm.